Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Regeneron
Regeneron
Sanofi, Regeneron eye Dupixent label expansion with promising COPD data
Medical Marketing and Media
Tue, 11/28/23 - 10:27 am
Sanofi
Regeneron
Dupixent
clinical trials
COPD
Regeneron stays out of ADC deal fray as in-house scientists tinker
Fierce Biotech
Wed, 11/15/23 - 11:08 am
Regeneron
antibody-drug conjugate
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Fierce Pharma
Thu, 11/2/23 - 11:48 am
Regeneron
Eylea
Roche
Vabysmo
Regeneron beats quarterly profit estimates on eczema treatment strength
Reuters
Thu, 11/2/23 - 11:33 am
Regeneron
earnings
Dupixent
Dupixent returns as top Rx, OTC brand for September
Medical Marketing and Media
Tue, 10/17/23 - 09:41 pm
Sanofi
Regeneron
Dupixent
DTC ads
pharma ads
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
Motley Fool
Fri, 10/6/23 - 10:05 am
Eli Lilly
Regeneron
Novo Nordisk
Top Pharma Ad Spenders in August 2023, AbbVie Splurges to Take Top Spots
Xtalks
Sun, 10/1/23 - 01:28 pm
pharma advertising
DTC ads
AbbVie
Skyrizi
Rinvoq
Regeneron
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Clinical Trials Arena
Fri, 09/29/23 - 11:38 am
Regeneron
clinical trials
bispecific antibodies
linvoseltamab
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
BioSpace
Wed, 08/23/23 - 09:54 am
HHS
Regeneron
JNJ
COVID-19
funding
Regeneron Expands Eylea’s Label with High-Dose Approval
BioSpace
Mon, 08/21/23 - 10:44 am
Regeneron
Eylea
FDA
Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease
BioSpace
Sun, 08/20/23 - 05:17 pm
Regeneron
FDA
CHAPLE disease
Veopoz
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Regeneron
Eylea
age-related macular degeneration
FDA
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Fierce Biotech
Wed, 08/9/23 - 10:10 am
Regeneron
hearing loss
Decibel Therapeutics
gene therapy
M&A
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Thu, 08/3/23 - 06:40 pm
Regeneron
Eylea
FDA
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
Thu, 08/3/23 - 11:23 am
earnings
Moderna Therapeutics
Regeneron
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »